MetaVia Inc. — Form 8-K
Filed July 9, 2026 · analyzed by the 8-K Agent
8-K
▲ Likely positive
significance 72/100
What the filing says
MetaVia announced July 9, 2026 that all enrolled patients in Phase 1 Part 3 of DA-1726 (dual GLP-1/glucagon agonist) successfully reached target doses of 48 mg (Part 3A, ~20 patients) and 64 mg (Part 3B, ~20 patients) across two 16-week titration cohorts. Topline data expected Q4 2026. Prior Phase 1 MAD data showed 9.1% mean weight loss at 48 mg in 8 weeks with improved waist circumference and glycemic measures.
Why this rating
Clinical milestone for lead asset of $3M-market-cap biotech; de-risks dose escalation ahead of pivotal data; material for small-cap pipeline company.
See more from July 9, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.